CRESCENT BIOPHARMA, INC. Net Fee Amt
CRESCENT BIOPHARMA, INC. (CBIO) had Net Fee Amt of $1.88 thousand as of 2026-09-18, per its S-8 filed 2026-09-18.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-09-18
- 2026-09-18: Net Fee Amt $1.88K.
- 2026-06-16: Net Fee Amt $69.05K.
| Period end | Net Fee Amt |
|---|---|
| 2026-09-18 | $1.88K S-8 · filed 2026-09-18 |
| 2026-06-16 | $69.05K S-3 · filed 2026-07-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |